With all of the back and forth lately I am reminded of some of the comments made by Maverick about the futility of trying to dissect every little detail (btw - not a lot of love between the two of us but he did make some good points from time to time). I have certainly been guilty of this myself. Here are some of my conclusions over the weekend.
1. Significant financial progress has been made this year with the addition of Woodford. Paying the bills and keeping the doors open is no longer a going concern. Unfavorable financing dripping with warrants and feeding the hungry short machine is no longer a concern. Woodford also provides a validation of the company, management, trial results (comprehensive clinical data from various compassionate use and other sources), and did I mention management.
2. Promising data from both programs have been released this year. We were given early glimpses of the efficacy of the L program through the 55 patient arm and the recent Direct data that may turn out to be very positive (time will tell). We are very fortunate as investors to have a sneak peak at what may come from these trials.
3. Additional treatment centers have come online to finish enrollment of L. We may even meet LP's prediction of enrollment completion in 2015.
4. Data from the Direct trial is promising enough to warrant further research in phase 2. That's really all we were realistically hoping for with the phase 1. The door is still open for the treatment to be a blockbuster.
5. There are still a lot of unknowns about the science, but that is actually a good thing for investors. If every detail and scenario were already known, the ship would have either already sank or sailed. A prerequisite to investing in a colossal winner is to put money on the line when risk is high (because of the unknowns) and probability of success is perceived to be low. Both are applicable to NWBO. We have the additional benefit of the various pieces of evidence that support a reasonable chance of success. I'll be buying the dips.
